IL106624A - Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them - Google Patents

Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them

Info

Publication number
IL106624A
IL106624A IL10662493A IL10662493A IL106624A IL 106624 A IL106624 A IL 106624A IL 10662493 A IL10662493 A IL 10662493A IL 10662493 A IL10662493 A IL 10662493A IL 106624 A IL106624 A IL 106624A
Authority
IL
Israel
Prior art keywords
denotes
alkyl
group
optionally
substituted
Prior art date
Application number
IL10662493A
Other languages
English (en)
Hebrew (he)
Other versions
IL106624A0 (en
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of IL106624A0 publication Critical patent/IL106624A0/xx
Publication of IL106624A publication Critical patent/IL106624A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL10662493A 1992-08-10 1993-08-09 Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them IL106624A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4226371 1992-08-10
DE4238423 1992-11-13

Publications (2)

Publication Number Publication Date
IL106624A0 IL106624A0 (en) 1993-12-08
IL106624A true IL106624A (en) 1999-01-26

Family

ID=25917371

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10662493A IL106624A (en) 1992-08-10 1993-08-09 Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them

Country Status (21)

Country Link
US (1) US5719279A (ar)
EP (1) EP0654033A1 (ar)
JP (1) JPH08500344A (ar)
KR (1) KR950702988A (ar)
CN (1) CN1043348C (ar)
AU (1) AU681348B2 (ar)
BG (1) BG62618B1 (ar)
CA (1) CA2140883A1 (ar)
CZ (1) CZ286459B6 (ar)
FI (1) FI950542A0 (ar)
HU (1) HUT65734A (ar)
IL (1) IL106624A (ar)
MX (1) MX9304819A (ar)
NZ (1) NZ254804A (ar)
PL (1) PL176389B1 (ar)
RU (1) RU2138500C1 (ar)
SG (1) SG55038A1 (ar)
SK (1) SK18595A3 (ar)
TW (1) TW252044B (ar)
UA (1) UA46697C2 (ar)
WO (1) WO1994003456A1 (ar)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW252044B (ar) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE69531555T2 (de) 1994-12-13 2004-06-17 Euroceltique S.A. Dreifachsubstituierte thioxanthine
JPH10508032A (ja) * 1994-12-13 1998-08-04 ユーロ−セルティーク，エス．エイ． アリールチオキサンチン類
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
WO1999031101A1 (en) * 1997-12-17 1999-06-24 University Of South Florida Adenosine receptor antagonists with improved bioactivity
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6376521B1 (en) 1998-07-10 2002-04-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A3 adenosine receptor antagonists
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
IL149487A0 (en) * 1999-11-12 2002-11-10 Biogen Inc Polycycloalkylpurine derivatives and pharmaceutical compositions containing the same
CN1187354C (zh) 1999-11-12 2005-02-02 拜奥根有限公司 腺苷受体拮抗剂以及制造和使用它们的方法
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
EP1252160B1 (en) 2000-01-14 2006-08-16 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methanocarba cycloalkyl nucleoside analogues
PT2298769E (pt) * 2001-02-24 2013-11-29 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como produto farmacêutico
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US7495004B2 (en) 2002-06-17 2009-02-24 Glaxo Group Limited Purine derivatives as liver X receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2004074247A2 (en) * 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
KR20060004959A (ko) 2003-04-25 2006-01-16 노바카르디아, 인코포레이션 신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US20090068101A9 (en) * 2003-06-09 2009-03-12 Endacea, Inc. A1 Adenosine Receptor Antagonists
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN103951667A (zh) 2006-05-04 2014-07-30 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008017670A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
CA2709772A1 (en) 2007-12-21 2009-07-09 Endacea, Inc. A1 adenosine receptor antagonists
US7928259B2 (en) * 2008-02-12 2011-04-19 Frx Polymers, Inc. Diaryl alkylphosphonates and methods for preparing same
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
JP5334511B2 (ja) * 2008-09-22 2013-11-06 日本精化株式会社 化粧料
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CA2755561A1 (en) * 2009-03-26 2010-09-30 Mapi Pharma Limited Process for the preparation of alogliptin
KR102328772B1 (ko) 2009-11-27 2021-11-19 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2507241A1 (en) 2009-12-02 2012-10-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
JP5876150B2 (ja) 2011-07-15 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キナゾリン、これらの調製及び医薬組成物中のこれらの使用
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
RU2643336C1 (ru) * 2016-10-03 2018-01-31 Общество с Ограниченной Ответственностью "Компания "ЭЛТА" СРЕДСТВО, ПРОЯВЛЯЮЩЕЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa (ВАРИАНТЫ)
CN109796453A (zh) * 2019-02-12 2019-05-24 南京纽邦生物科技有限公司 一种1,7-二甲基黄嘌呤的制备方法
EP4229059A1 (en) 2020-10-15 2023-08-23 Rheinische Friedrich-Wilhelms-Universität Bonn 3-substituted xanthine derivatives as mrgprx4 receptor modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
ES2130138T3 (es) * 1990-10-18 1999-07-01 Kyowa Hakko Kogyo Kk Derivado de xantina.
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
TW252044B (ar) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5366977A (en) * 1992-09-29 1994-11-22 The United States Of America, As Represented By The Department Of Health And Human Services Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners

Also Published As

Publication number Publication date
WO1994003456A1 (de) 1994-02-17
FI950542A (fi) 1995-02-08
IL106624A0 (en) 1993-12-08
HU9302302D0 (en) 1993-10-28
BG99489A (bg) 1996-01-31
NZ254804A (en) 1997-01-29
MX9304819A (es) 1994-02-28
CN1043348C (zh) 1999-05-12
SK18595A3 (en) 1995-07-11
AU4707193A (en) 1994-03-03
HUT65734A (en) 1994-07-28
AU681348B2 (en) 1997-08-28
JPH08500344A (ja) 1996-01-16
SG55038A1 (en) 1998-12-21
CN1086818A (zh) 1994-05-18
BG62618B1 (bg) 2000-03-31
PL176389B1 (pl) 1999-05-31
PL307397A1 (en) 1995-05-15
TW252044B (ar) 1995-07-21
FI950542A0 (fi) 1995-02-08
EP0654033A1 (de) 1995-05-24
RU2138500C1 (ru) 1999-09-27
CZ34895A3 (en) 1995-10-18
CZ286459B6 (en) 2000-04-12
US5719279A (en) 1998-02-17
KR950702988A (ko) 1995-08-23
RU95109100A (ru) 1996-12-27
CA2140883A1 (en) 1994-02-17
UA46697C2 (uk) 2002-06-17

Similar Documents

Publication Publication Date Title
IL106624A (en) Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them
AU683270B2 (en) Novel chemical compounds having PDE-IV inhibition activity
RU2269529C2 (ru) Производные 8-хинолинксантина и 8-изохинолинксантина в качестве ингибиторов фосфоэстеразы pde 5
KR101564233B1 (ko) 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도
US6187780B1 (en) Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
AU2001273921A1 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
JP2003506375A (ja) チロシンタンパク質キナーゼｓｙｋのプリン誘導体阻害剤
JP2003505461A (ja) ８−フェニル−６，９−ジヒドロ−［１，２，４］トリアゾロ［３，４−ｉ］プリン−５−オン誘導体
JPS626555B2 (ar)
JP3020281B2 (ja) 新規なトリアゾロプリン類、その調製方法及び医薬組成物としての使用
WO1999062905A1 (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
CA2328264A1 (en) Novel asymmetrically substituted xanthine derivatives, method for producing them and their use as medicaments with an adenosine-antagonistic effect
DE4325254A1 (de) Unsymmetrisch substituierte Xanthine
US6919337B2 (en) 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US6248746B1 (en) 3-(arylalkyl) xanthines
CA2327395C (en) New imidazotriazolopyrimidines, processes for preparing them and their use as pharmaceutical compositions
JPS635392B2 (ar)
CA2242097C (en) Imidazotriazolopyrimidines, process for preparing them and their use as pharmaceutical compositions
US7361661B2 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force